Prediction Model of Colorectal Adenoma Recurrence-Carcinogenesis Risk With TCM-WM Multimodal Feature Fusion
Study on the Prediction Model of Recurrence and Carcinogenesis Risk of Colorectal Adenoma Based on the Fusion of Traditional Chinese and Western Medicine Multimodal Features
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Hongtao Wei
- Phone Number: +86 13811216906
- Email: gulvzhe@126.com
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100000
- Recruiting
- Beijing Friendship Hospital Affiliated to Capital Medical University
-
Contact:
- Shutian Zhang
- Email: zhangstyy@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Meet the diagnostic criteria for colorectal adenoma (Western medicine) and the relevant TCM syndromes.
- Aged 18 years or older.
- Willing to undergo regular follow-up examinations (including colonoscopy and laboratory tests) and sign the informed consent form.
Exclusion Criteria:
- Pregnant or lactating women.
- History of Crohn's disease, ulcerative colitis, or other malignancies.
- Previous history of radiotherapy, chemotherapy, or gastrointestinal surgery.
- Hereditary polyposis syndromes (e.g., familial adenomatous polyposis, MUTYH-associated polyposis, or hamartomatous polyposis syndrome).
- Severe cognitive impairment, dementia, or mental illness.
- Severe cardiovascular or cerebrovascular diseases, or hematological system disorders.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Colorectal Adenoma
Patients diagnosed with colorectal adenoma who have undergone endoscopic resection (including endoscopic mucosal resection [EMR], endoscopic submucosal dissection [ESD], or cold snare polypectomy [CSP], as appropriate for lesion characteristics) and whose resected specimen has been pathologically confirmed as colorectal adenoma (excluding adenocarcinoma, hyperplastic polyps, or other non-adenomatous lesions) are eligible for enrollment.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Advanced Adenoma Recurrence
Time Frame: From enrollment to study completion, up to 3 years (average 1.5 years)
|
From enrollment to study completion, up to 3 years (average 1.5 years)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Adenoma Recurrence
Time Frame: From enrollment to study completion, up to 3 years (average 1.5 years)
|
From enrollment to study completion, up to 3 years (average 1.5 years)
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Carcinogenesis
Time Frame: From enrollment to study completion, up to 3 years (average 1.5 years)
|
From enrollment to study completion, up to 3 years (average 1.5 years)
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Wang RJ, Zhang XL, Cai JD, Wang MH, Liu JQ, Xu Y. [Standardized diagnosis and treatment of colorectal polyps]. Zhonghua Wei Chang Wai Ke Za Zhi. 2024 Jun 25;27(6):583-590. doi: 10.3760/cma.j.cn441530-20240416-00143. Chinese.
- Roslan NH, Makpol S, Mohd Yusof YA. A Review on Dietary Intervention in Obesity Associated Colon Cancer. Asian Pac J Cancer Prev. 2019 May 25;20(5):1309-1319. doi: 10.31557/APJCP.2019.20.5.1309.
- Terasaki M, Kubota A, Kojima H, Maeda H, Miyashita K, Kawagoe C, Mutoh M, Tanaka T. Fucoxanthin and Colorectal Cancer Prevention. Cancers (Basel). 2021 May 14;13(10):2379. doi: 10.3390/cancers13102379.
- Kanth P, Inadomi JM. Screening and prevention of colorectal cancer. BMJ. 2021 Sep 15;374:n1855. doi: 10.1136/bmj.n1855.
- Kim SH, Park DH, Lim YJ. Impact of Diet on Colorectal Cancer Progression and Prevention: From Nutrients to Neoplasms. Korean J Gastroenterol. 2023 Aug 25;82(2):73-83. doi: 10.4166/kjg.2023.079.
- Zhou E, Rifkin S. Colorectal Cancer and Diet: Risk Versus Prevention, Is Diet an Intervention? Gastroenterol Clin North Am. 2021 Mar;50(1):101-111. doi: 10.1016/j.gtc.2020.10.012.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 2024ZD0520802
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.